cinnamaldehyde thiosemicarbazone profile

cinnamaldehyde thiosemicarbazone: has antimicrobial activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	7245310
CHEMBL ID	1276230
SCHEMBL ID	1435428
MeSH ID	M0538952

Synonym
AKOS002388566
smr000236346
MLS000722983
wln: suyzmnu2u1r
hydrazinecarbothioamide, 2-(3-phenyl-2-propenylidene)-
cinnamaldehyde thiosemicarbazone
1-[(3-phenyl-2-propenylidene)amino]-2-thiourea
semicarbazide, 1-(3-phenyl-2-propenylidene)-3-thio-
nsc-706
nsc706
semicarbazide, 1-cinnamylidene-3-thio-
5351-70-2
1-(3-phenyl-2-propenylidene)-3-thiosemicarbazide
1-cinnamylidenethiosemicarbazide
[(1-aza-4-phenylbuta-1,3-dienyl)amino]aminomethane-1-thione
[(e)-[(e)-3-phenylprop-2-enylidene]amino]thiourea
1-(3-phenylallylidene)thiosemicarbazide
AKOS000304446
HMS1609C18
NCGC00246607-01
CHEMBL1276230 ,
132200-89-6
bdbm50356196
SCHEMBL1435428
SHUQFXIRXYXNOZ-HCFISPQYSA-N
hydrazinecarbothioamide, 2-[3-phenyl-2-propen-1-ylidene]-
CCG-234062
mfcd00170595
[(e)-[(2e)-3-phenylprop-2-en-1-ylidene]amino]thiourea
(1e,2e)-3-phenyl-2-propenal thiosemicarbazone
sr-01000080159
SR-01000080159-1
STL583812
(2e)-2-[(2e)-3-phenylprop-2-en-1-ylidene]hydrazinecarbothioamide
mfcd08144060
2-(3-phenylallylidene)hydrazinecarbothioamide
A914476
Z49561492

Protein Targets (15)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Cruzipain	Trypanosoma cruzi	Potency	20.4839	0.0020	14.6779	39.8107	AID1476; AID1478
glp-1 receptor, partial	Homo sapiens (human)	Potency	12.5893	0.0184	6.8060	14.1254	AID624417
TDP1 protein	Homo sapiens (human)	Potency	5.8048	0.0008	11.3822	44.6684	AID686978; AID686979
67.9K protein	Vaccinia virus	Potency	0.8972	0.0001	8.4406	100.0000	AID720579; AID720580
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	89.1251	0.7079	36.9043	89.1251	AID504333
huntingtin isoform 2	Homo sapiens (human)	Potency	35.4813	0.0006	18.4198	1,122.0200	AID1688
DNA polymerase beta	Homo sapiens (human)	Potency	25.1189	0.0224	21.0102	89.1251	AID485314
DNA polymerase eta isoform 1	Homo sapiens (human)	Potency	19.9526	0.1000	28.9256	213.3130	AID588591
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	10.9740	0.0079	8.2332	1,122.0200	AID2546; AID2551
geminin	Homo sapiens (human)	Potency	14.5810	0.0046	11.3741	33.4983	AID624296
muscleblind-like protein 1 isoform 1	Homo sapiens (human)	Potency	1.4125	0.0041	9.9625	28.1838	AID2675
neuropeptide S receptor isoform A	Homo sapiens (human)	Potency	25.1189	0.0158	12.3113	615.5000	AID1461
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	10.0000	1.7783	16.2081	35.4813	AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Polyphenol oxidase 2	Agaricus bisporus	Ki	4.4500	0.0006	3.2883	8.8900	AID1571731
Urease	Canavalia ensiformis (jack bean)	IC50 (µMol)	0.4570	0.4570	3.2023	8.5900	AID625341
Urease	Canavalia ensiformis (jack bean)	Ki	0.4070	0.4070	0.4070	0.4070	AID625341
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Polyphenol oxidase 2	Agaricus bisporus	Kis	8.8500	2.9000	5.3300	8.8500	AID1571731
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Process	via Protein(s)	Taxonomy
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Process	via Protein(s)	Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Process	via Protein(s)	Taxonomy
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (51)

Assay ID	Title	Year	Journal	Article
AID1381729	Inhibition of Leishmania major PTR1 at 50 uM using H2B as substrate in presence of NADPH by photometric analysis relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381712	Cytotoxicity against human U2OS cells assessed as viable cells at 50 uM after 72 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381710	Cytotoxicity against human 786-O cells assessed as inhibition of mitochondrial viability at 10 uM after 6 hrs by CMXRos staining based assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381711	Cytotoxicity against human THP1 cells assessed as viable cells at 100 uM after 72 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID536024	Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y assessed as viability at 40 uM after 11 days by trypan blue exclusion assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.
AID1381716	Selectivity index, ratio of CC50 for human U2OS cells to EC50 for Trypanosoma cruzi amastigote form	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID536021	Inhibition of Trypanosoma cruzi cruzaine pre-incubated for 10 mins	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.
AID1381691	Antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream form after 72 hrs by SYBR Green assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID536027	Cytotoxicity against BALB/c mouse Splenocyte assessed as non-cytotoxic concentration after 24 hrs by [3H]-thymidine incorporation assay relative to control	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.
AID1381715	Cytotoxicity against human U2OS cells assessed as decrease in viable cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID536020	Inhibition of Trypanosoma cruzi cruzaine at 100 uM pre-incubated for 10 mins	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.
AID1381689	Antileishmanial activity against Leishmania infantum amastigote form assessed as parasite growth inhibition at 50 uM after 72 hrs by steady-Glo reagent based assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381704	Inhibition of human microsomal CYP2C19 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID536025	Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y assessed as viability after 11 days by trypan blue exclusion assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.
AID1381728	Inhibition of Trypanosoma brucei PTR1 at 50 uM using H2B as substrate in presence of NADPH by photometric analysis relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381705	Inhibition of human microsomal CYP2D6 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381690	Antitrypanosomal activity against Trypanosoma cruzi amastigote form infected in human U2OS cells assessed as parasite growth inhibition at 50 uM after 72 hrs relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381703	Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1233717	Cytotoxicity against BALB/c mouse splenocytes assessed as reduction in cell viability incubated for 24 hrs by beta-radiation counting based [3H]-thymidine incorporation assay	2015	European journal of medicinal chemistry, Jul-15, Volume: 100	Thiosemicarbazones as Aedes aegypti larvicidal.
AID1381696	Inhibition of human microsomal CYP1A2 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381702	Inhibition of human ERG at 10 uM incubated for 2 hrs by fluorescence polarisation assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381693	Antitrypanosomal activity against Trypanosoma cruzi amastigote form infected in human U2OS cells assessed as parasite growth inhibition after 72 hrs	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1571731	Reversible mixed-type inhibition of mushroom tyrosinase by Lineweaver-Burk plot analysis	2019	MedChemComm, Mar-01, Volume: 10, Issue:3	Thiosemicarbazones with tyrosinase inhibitory activity.
AID1233716	Larvicidal activity against Aedes aegypti L4 stage larvae assessed as induction of larval mortality incubated for 48 hrs	2015	European journal of medicinal chemistry, Jul-15, Volume: 100	Thiosemicarbazones as Aedes aegypti larvicidal.
AID1381695	Potentiation of methotrexate-induced antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream form at 10 uM after 72 hrs by resazurin dye-based assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID625341	Inhibition of jack bean urease assessed as ammonia production after 30 mins by indophenol method	2011	European journal of medicinal chemistry, Nov, Volume: 46, Issue:11	Synthesis, biological assay in vitro and molecular docking studies of new Schiff base derivatives as potential urease inhibitors.
AID1381697	Potentiation of methotrexate-induced antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream form at 10 uM after 72 hrs by resazurin dye-based assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID536019	Inhibition of Trypanosoma cruzi cruzaine in presence of 0.01% Triton X-100	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.
AID1381688	Antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream form assessed as parasite growth inhibition at 50 uM after 72 hrs by SYBR Green assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381706	Inhibition of human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381694	Antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream form at 10 uM after 72 hrs by resazurin dye-based assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381708	Cytotoxicity against human A549 cells assessed as growth inhibition at 10 uM after 48 hrs by CellTiter-Glo assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID536026	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Y assessed as viability after 24 hrs by trypan blue exclusion assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.
AID536023	Inhibition of Trypanosoma cruzi cruzaine in absence of 0.01% Triton X-100	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.
AID1381707	Inhibition of recombinant full-length human aurora B kinase expressed in baculovirus system at 10 uM using MBP as substrate incubated for 45 mins by ADP-glo kinase assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1381709	Cytotoxicity against human WI38 cells assessed as growth inhibition at 10 uM after 48 hrs by CellTiter-Glo assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (13.33)	29.6817
2010's	10 (66.67)	24.3611
2020's	3 (20.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (6.67%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	14 (93.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	2.41	1	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
miltefosine miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.	2.17	1	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor
kojic acid [no description available]	3.31	1	4-pyranones; enol; primary alcohol	Aspergillus metabolite; EC 1.10.3.1 (catechol oxidase) inhibitor; EC 1.10.3.2 (laccase) inhibitor; EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor; EC 1.14.18.1 (tyrosinase) inhibitor; EC 1.4.3.3 (D-amino-acid oxidase) inhibitor; NF-kappaB inhibitor; skin lightening agent
pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.	2.17	1	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
acrolein [no description available]	2.41	1	enal	herbicide; human xenobiotic metabolite; toxin
benzonidazole benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.	2.5	2	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug
methotrexate [no description available]	2.17	1	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazole 2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazole: structure in first source	2.17	1
cinnamaldehyde 3-phenylprop-2-enal : A member of the class of cinnamaldehydes that is prop-2-enal in which a hydrogen at position 3 has been replaced by a phenyl group. The configuration of the double bond is not specified; the name "cinnamaldehyde" is widely used to refer to the E (trans) isomer.. (E)-cinnamaldehyde : The E (trans) stereoisomer of cinnamaldehyde, the parent of the class of cinnamaldehydes.	2.41	1	3-phenylprop-2-enal; cinnamaldehydes	antifungal agent; EC 4.3.1.24 (phenylalanine ammonia-lyase) inhibitor; flavouring agent; hypoglycemic agent; plant metabolite; sensitiser; vasodilator agent
thiosemicarbazide thiosemicarbazide: glutamate decarboxylase antagonist; structure given in first source. hydrazinecarbothioamide : A member of the class of thioureas that is thiourea in which a hydrogen of one of the amino groups is replaced by an amino group.	2.41	1	hydrazines; thiocarboxamide; thioureas
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	2.06	1	one-carbon compound; thioureas; ureas	antioxidant; chromophore
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	2.17	1	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
pellitorine pellitorine: consists of piper sylvaticum Roxb.; structure	2.11	1	fatty amide	metabolite
Pipercide [no description available]	2.11	1	benzodioxoles
guineensine guineensine: an Acyl-CoA: cholesterol acyltransferase inhibitor, from the fruits of Piper longum; structure in first sourc	2.11	1	benzodioxoles
3-hydroxy-4-methoxybenzaldehyde thiosemicarbazone 3-hydroxy-4-methoxybenzaldehyde thiosemicarbazone: inhibits cabbage butterfly larvae phenoloxidase; structure in first source	3.31	1
retrofractamide a retrofractamide A: structure in first source	2.11	1	benzodioxoles
salicylaldehyde thiosemicarbazone salicylaldehyde thiosemicarbazone: structure given in first source	3.69	2

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
American Trypanosomiasis [description not available]	2.17	1
Chagas Disease Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.	2.17	1

cinnamaldehyde thiosemicarbazone

Description

Cross-References

Synonyms (38)

Protein Targets (15)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (18)

Molecular Functions (10)

Ceullar Components (9)

Bioassays (51)

Research

Studies (15)

Market Indicators

Research Demand Index: 11.76

Study Types

cinnamaldehyde thiosemicarbazone

Description

Cross-References

Synonyms (38)

Protein Targets (15)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (18)

Molecular Functions (10)

Ceullar Components (9)

Bioassays (51)

Research

Studies (15)

Market Indicators

Research Demand Index: 11.76

Study Types

Related Drugs (18)

Related Conditions (6)